A Phase 2 interventional study of Bevacizumab HAI plus systemic chemotherapy and HAI plus systemic chemotherapy in Hepatic Metastases, Colon Cancer and Rectal Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Completed at 5 sites in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Colonic Neoplasms by Memorial Sloan Kettering Cancer Center — 4 open to participants now, 9 under way, none of them phase 3. Colonic Neoplasms · Memorial Sloan Kettering Cancer Center.
Among the 53 studies in Colonic Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 6th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2004, is one of 15 in phase 2, and was the 25th registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.
Browse Colonic Neoplasms studies →4 of the 53 studies in Colonic Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Healthy volunteers
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 19 · Phase 3 1
First in 1981; this study’s year is marked. 3 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is close to the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.
Median enrollment 37 across the 24 interventional studies, 80 across the 14 observational. Of the 44 that completed or were terminated, 7 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
7 of the studies in Colonic Neoplasms by Memorial Sloan Kettering Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00582621Memorial Sloan Kettering Cancer CenterAscertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders | 2026-12 |
| NCT00579163Memorial Sloan Kettering Cancer CenterAscertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | 2026-12 |
| NCT04668872Memorial Sloan Kettering Cancer CenterBiopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation | 2026-12-07 |
| NCT00579514Memorial Sloan Kettering Cancer CenterGermline Alterations of Tumor Susceptibility Genes in New York Cancer Patients | 2027-03 |
| NCT05793593Memorial Sloan Kettering Cancer CenterA Study of Using Social Networks to Encourage Three Peers to Complete Screening for Colorectal Cancer | 2027-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 53 studies in Colonic Neoplasms by Memorial Sloan Kettering Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the addition of bevacizumab, to hepatic arterial therapy with floxuridine (FUDR) and dexamethasone (Dex) (regional chemotherapy), and either oxaliplatin or CPT-11, plus 5-fluorouracil and leucovorin (systemic chemotherapy) will increase disease free survival in patients who have undergone liver resection. The patient will be randomized (a computer generated decision as in the flip of a coin) to receive, or not to receive bevacizumab in addition to regional and systemic chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Lab values within 14 days prior to registration:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bevacizumab in addition to HAI plus systemic chemotherapy
Drug: Bevacizumab HAI plus systemic chemotherapy
HAI plus systemic chemotherapy alone
Drug: HAI plus systemic chemotherapy
Oxaliplatin (mg/m2) IV, over 2 hours, 5 FU (mg/m2) continuous infusion, over two days, leucovorin (mg/m2) IV, over 2 hours
Irinotecan (mg/m2) IV, over 30 minutes, 5 FU (mg/m2) continuous infusion over two days, leucovorin (mg/m2) IV, over 30 minutes
Relapse Free Survival/RFS
To determine whether the addition of concurrent intravenous bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancer
Time frame: 1 year
Number of Participants Assessed for Toxicity
To assess toxicity
Time frame: 7.5 months
To Determine Survival
Time frame: 2 years
To Compare Plasma Levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ Circulating Endothelial Progenitors
Time frame: 2 years
To Assess the Expression Pattern of VEGFR1, VEGFR2 (Angiogenesis), and VEGFR3 (Lymphangiogenesis) and Their Cognate Ligands (VEGF-A, VEGF-C, VEGF-D), and Correlate With Patient Progression and Survival Following
Time frame: 2 years
| Milestone | Bevacizumab in Addition to HAI Plus Systemic Chemotherapy | HAI Plus Systemic Chemotherapy Alone |
|---|---|---|
| Started | 35 | 38 |
| Completed | 24 | 30 |
| Not completed | 11 | 8 |
| Withdrew: Adverse event | 6 | 4 |
| Withdrew: Physician decision | 3 | 3 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
To determine whether the addition of concurrent intravenous bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancer
| percentage of participants at 1 year | Bevacizumab in Addition to HAI Plus Systemic Chemotherapy | HAI Plus Systemic Chemotherapy Alone |
|---|---|---|
| Relapse Free Survival/RFS | 71 (52 to 83) | 83 (66 to 92) |
To assess toxicity
| Participants | Bevacizumab in Addition to HAI Plus Systemic Chemotherapy | HAI Plus Systemic Chemotherapy Alone |
|---|---|---|
| Number of Participants Assessed for Toxicity | 35 | 38 |
| Participants | Bevacizumab in Addition to HAI Plus Systemic Chemotherapy | HAI Plus Systemic Chemotherapy Alone |
|---|---|---|
| Alive | 17 | 20 |
| Dead | 18 | 18 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab in Addition to HAI Plus Systemic Chemotherapy | 18/35 (51.4%) | 16/35 (45.7%) | 30/35 (85.7%) |
| HAI Plus Systemic Chemotherapy Alone | 18/38 (47.4%) | 10/38 (26.3%) | 9/38 (23.7%) |
| Event | Bevacizumab in Addition to HAI Plus Systemic Chemotherapy | HAI Plus Systemic Chemotherapy Alone |
|---|---|---|
| DiarrheaGastrointestinal disorders | 4/35 | 4/38 |
| Pain - Abdomen NOSGastrointestinal disorders | 1/35 | 4/38 |
| Liver dysfunction/failureHepatobiliary disorders | 2/35 | 0/38 |
| Thrombosis/thrombus/embolismVascular disorders | 2/35 | 0/38 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/35 | 2/38 |
| Bilirubin (hyperbilirubinemia)Investigations | 1/35 | 0/38 |
| Hemorrhage/Bleeding, otherInjury, poisoning and procedural complications | 1/35 | 0/38 |
| Infection w/ Gr 3/4 neut, Anal/perianalInfections and infestations | 1/35 | 0/38 |
| Infection, otherInfections and infestations | 1/35 | 0/38 |
| Musculoskeletal/Soft Tissue - OtherMusculoskeletal and connective tissue disorders | 1/35 | 0/38 |
| Event | Bevacizumab in Addition to HAI Plus Systemic Chemotherapy | HAI Plus Systemic Chemotherapy Alone |
|---|---|---|
| Alkaline phosphatase two fold or higher increaseInvestigations | 11/35 | 6/38 |
| DiarrheaGastrointestinal disorders | 6/35 | 3/38 |
| Bilirubin > 3mg/dLInvestigations | 5/35 | 0/38 |
| Biliary stentsHepatobiliary disorders | 4/35 | 0/38 |
| ThrombosisVascular disorders | 3/35 | 0/38 |
| Abdominal PainGastrointestinal disorders | 1/35 | 3/38 |
| Age, Continuous(years) | Bevacizumab in Addition to HAI Plus Systemic Chemotherapy | HAI Plus Systemic Chemotherapy Alone | Total |
|---|---|---|---|
| Mean | 53 (35 to 74) | 54 (29 to 77) | 53.5 (29 to 77) |
| Sex: Female, Male(Participants) | Bevacizumab in Addition to HAI Plus Systemic Chemotherapy | HAI Plus Systemic Chemotherapy Alone | Total |
|---|---|---|---|
| Female | 19 | 16 | 35 |
| Male | 16 | 22 | 38 |
| Ethnicity (NIH/OMB)(Participants) | Bevacizumab in Addition to HAI Plus Systemic Chemotherapy | HAI Plus Systemic Chemotherapy Alone | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 35 | 36 | 71 |
| Race (NIH/OMB)(Participants) | Bevacizumab in Addition to HAI Plus Systemic Chemotherapy | HAI Plus Systemic Chemotherapy Alone | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 35 | 35 | 70 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Bevacizumab in Addition to HAI Plus Systemic Chemotherapy | HAI Plus Systemic Chemotherapy Alone | Total |
|---|---|---|---|
| United States | 35 | 38 | 73 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Nov 2004, a primary completion of Mar 2025 and a completion of Mar 2025. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2026, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →